Lilly chief exec affirms company is not for sale

Share this article:

Eli Lilly's chief executive said his company is not for sale, boasts a
healthy pipeline and plans on producing top growth for years to
come, during television appearance yesterday.
Sidney Taurel said on CNBC Thursday that, historically, mergers
have not created shareholder value "in a sustainable fashion."
The chief executive also discussed a Dec. 2 lawsuit Lilly filed in Indiana district court seeking to stop Barr Pharmaceuticals from marketing a generic version of Zyprexa, Lilly's largest drug with sales of $233 million in the 12 months ending in September. "We really don't know when the judgment will come," Taurel said.
Speaking on pharma companies' relationships with consumers following the withdrawal of Vioxx, Taurel said, "This is the most challenging period I've seen in my career."                       

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Judge blocks FDA bid to allow generic Precedex

Judge blocks FDA bid to allow generic Precedex

The US District Court for Maryland granted Hospira a temporary restraining order (TRO) against FDA, after the agency determined that potential generic competitors of the company's injectable sedation drug Precedex ...

GSK drug gets aplastic anemia indication

GSK drug gets aplastic anemia indication

Promacta was previously indicated for chronic immune thrombocytopenia.

Five things for Pharma Marketers to know: Wednesday, August 27

Five things for Pharma Marketers to know: Wednesday, ...

Allergan sets a shareholder voting date, Novo describes the types of acquisitions it will consider, and the AstraZeneca-Pfizer talks can now reopen.